Next Article in Journal / Special Issue
Characteristics and Management of Candidaemia Episodes in an Established Candida auris Outbreak
Previous Article in Journal
Feasibility Study of the World Health Organization Health Care Facility-Based Antimicrobial Stewardship Toolkit for Low- and Middle-Income Countries
Previous Article in Special Issue
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
Article

Candida auris Bloodstream Infections in Russia

Almazov National Medical Research Centre, 2 Akkuratova str., 197341 St. Petersburg, Russia
*
Author to whom correspondence should be addressed.
Antibiotics 2020, 9(9), 557; https://doi.org/10.3390/antibiotics9090557
Received: 31 July 2020 / Revised: 22 August 2020 / Accepted: 28 August 2020 / Published: 30 August 2020
(This article belongs to the Special Issue Diagnosis,Resistance and Treatment of Infections by Candida auris)
Candida auris—a fungus (yeast) that can cause hospital outbreaks was first recognized in 2009. The authors report data on 38 cases of C. auris bloodstream infections in multidisciplinary hospitals situated in two distantly located regions of Russia, considering predisposing factors, antifungal susceptibility of isolates, treatment, and outcomes. Interhospital transfers of patients and labor migration contributed to the spread of C. auris. The South Asian lineage of the studied strains was indicated by K143R substitution in ERG11 gene and phylogenetic analysis of internal transcribed spacer and D1-D2 domain. All isolates from C. auris candidemia cases were susceptible to echinocandins. High-level resistance to fluconazole and resistance to amphotericin B were present in the majority of strains. The overall all-cause mortality rate in C. auris bloodstream infections was 55.3% and the 30-day all-cause mortality rate 39.5%. The attributable mortality was 0%. Eradication of C. auris from blood was associated with the favourable outcomes in patients. It was achieved irrespective of whether antifungal preparations within or outside the susceptibility range were administered. Further international surveillance and studies providing consensus guidelines for the management of C. auris infections are needed. View Full-Text
Keywords: treatment; echinocandins; azoles; susceptibility; amphotericin B; mortality; attributable mortality; risk factors; K143R substitution; EGR11 gene; phylogenetic analysis treatment; echinocandins; azoles; susceptibility; amphotericin B; mortality; attributable mortality; risk factors; K143R substitution; EGR11 gene; phylogenetic analysis
Show Figures

Figure 1

MDPI and ACS Style

Barantsevich, N.E.; Vetokhina, A.V.; Ayushinova, N.I.; Orlova, O.E.; Barantsevich, E.P. Candida auris Bloodstream Infections in Russia. Antibiotics 2020, 9, 557. https://doi.org/10.3390/antibiotics9090557

AMA Style

Barantsevich NE, Vetokhina AV, Ayushinova NI, Orlova OE, Barantsevich EP. Candida auris Bloodstream Infections in Russia. Antibiotics. 2020; 9(9):557. https://doi.org/10.3390/antibiotics9090557

Chicago/Turabian Style

Barantsevich, Natalia E., Antonina V. Vetokhina, Natalia I. Ayushinova, Olga E. Orlova, and Elena P. Barantsevich. 2020. "Candida auris Bloodstream Infections in Russia" Antibiotics 9, no. 9: 557. https://doi.org/10.3390/antibiotics9090557

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop